NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

This was a first-in-human study to check the safety of a new eye injection called PMC-403 for wet age-related macular degeneration (AMD). It involved 17 participants whose vision was still declining despite receiving standard anti-VEGF injections. The main goal was to find the hi…

This was a first-in-human study to check the safety of a new drug, OLX10212, for wet age-related macular degeneration (AMD). It involved 21 patients who received injections of the drug into their eye. The main goal was to see if the treatment was safe and tolerable, while also lo…

This study aimed to check the long-term safety of a drug called faricimab for people with wet age-related macular degeneration, a leading cause of vision loss. Over 1,000 patients who had already completed earlier studies received the drug via eye injections at personalized inter…

This completed Phase 3 study tested whether a new, potentially more affordable biosimilar version of the drug aflibercept (FYB203) works as well and is as safe as the established drug Eylea for treating wet age-related macular degeneration (AMD). The study involved 434 patients w…

This study tested if a new drug called LUBT010 is as effective and safe as the established treatment Lucentis for wet age-related macular degeneration, a major cause of vision loss. About 600 participants aged 50+ with active disease received monthly eye injections of either drug…

This study aimed to understand how much of a high-dose eye medication gets into the bloodstream when injected into both eyes. It involved 51 adults with diabetic macular edema or 'wet' age-related macular degeneration. Researchers measured the highest drug concentration in partic…

This study aimed to measure the thickness of specific eye tissues in patients with two common vision conditions (neovascular age-related macular degeneration and diabetic macular edema) and compare them to healthy volunteers. Researchers used a special imaging scan to take these …